Related Experiment Videos
[Clinical trial and basic study on the tissue transfer of cefminox]
The Japanese Journal of Antibiotics
|May 1, 1985
Summary
Cefminox (CMNX) shows high efficacy and safety for gynecological infections, proving effective in treating various conditions like Bartholin
Area of Science:
- Pharmacology and Therapeutics
- Infectious Diseases
- Obstetrics and Gynecology
Context:
- Gynecological infections pose significant health challenges.
- Need for effective and safe antibiotic treatments in obstetrics and gynecology.
- Cefminox (CMNX) is an antibiotic investigated for its therapeutic potential.
Purpose:
- To evaluate the clinical efficacy and safety of Cefminox (CMNX) in treating gynecological infections.
- To determine the pharmacokinetic profile of Cefminox (CMNX) in serum and pelvic tissues.
Summary:
- Cefminox (CMNX) was administered at 1g to 9 patients with conditions including Bartholin's abscess, pyometra, and pelvic peritonitis, achieving good clinical results in all cases.
- Pharmacokinetic analysis showed Cefminox (CMNX) concentrations exceeding 20 µg/ml in serum and 10 µg/g in pelvic tissues for up to 8 hours post-administration.
- No side effects or laboratory abnormalities were observed, indicating a favorable safety profile.
Impact:
- Cefminox (CMNX) demonstrates significant promise as a highly effective and safe antibiotic for obstetric and gynecological infections.
- The drug's sustained concentrations in target tissues support its clinical efficacy.
- Findings support the use of Cefminox (CMNX) in clinical practice for managing these infections.